To advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.
Call for Nominations to the KHI Board of Directors
The KHI Nominating Committee would like to announce a call for nominations for the Board of Directors. To self-nominate or submit a candidate for consideration, please send the candidate's CV or resume along with a one-page explanation (no more than 500 words) of the candidate's expertise, relevant experience, and potential contribution to the KHI Board of Directors.
KHI must receive this application by email to firstname.lastname@example.org by Tuesday, August 16, at 5:00pm EST. The KHI Nominating Committee will review the candidates and develop a slate for approval by the KHI Board of Directors. To view the Call for Nominations, please click here.
KHI Attends the White House Organ Summit
KHI is pleased to support President Barack Obama's call to action through its attendance at the White House Organ Summit on Monday, June 13. This Summit will examine ways to improve the outcomes for individuals waiting for organ transplants and support living donors in addition to improving kidney patient care options and transplantation access.
KHI has submitted the following commitment statement in support of the White House Initiative
The Kidney Health Initiative, a public-private partnership established by the U.S. Food and Drug Administration and the American Society of Nephrology and composed of more than 75 member organizations, will initiate the development of a roadmap that will describe scientific, technical, and regulatory milestones needed to achieve the goal of creating a bioartificial or bioengineered alternative to dialysis as renal replacement therapy. The roadmap will also consider challenges, provide "state of the art" expectations for entrepreneurs and other technology developers, and spur innovation in producing functioning kidney replacements by engaging stakeholders, identifying research priorities to alleviate critical knowledge gaps, and advancing the science of alternatives to dialysis.
The roadmap was presented as a project proposal at the Fourth Annual KHI Stakeholders Meeting in May 2016. The proposal can be viewed on the KHI Meetings Page.
KHI Announces New Members of the Patient and Family Partnership Council (PFPC)
The KHI Patient and Family Partnership Council (PFPC) was established in May 2015. KHI is pleased to welcome three new members to the PFPC, fulfilling the organizational structure as a 10 member Council.
Pamela Duquette, is the mother of a child with FSGS and represents NephCure International.
Nichole Jefferson has experienced both peritoneal and hemo-dialysis treatments. Nichole received a kidney transplant in the summer of 2008.
David White has experienced in-center hemo-dialysis, in-center nocturnal hemo-dialysis, and peritoneal dialysis. Dave received a kidney transplant in the summer of 2015.
To learn more about the PFPC or its members, please visit the PFPC page.
Fourth Annual KHI Stakeholders Meeting
The Fourth Annual KHI Stakeholders Meeting took place at the DoubleTree by Hilton Hotel Washington DC- Silver Spring in Silver Spring, MD on May 25-26, 2016. The Stakeholders Meeting brought together our diverse membership from the kidney community to connect members across different fields, share ideas, collect feedback, and collaborate on new and proposed projects.
Please visit the KHI Meetings Page for more information on the Fourth Annual KHI Stakeholders Meeting.
KHI Annual Report 2014-2015
On behalf of the Board of Directors, we would like to thank the KHI membership for their participation in KHI, which has seen its membership grow from 47 organizations in September 2013, to more than 75 organizations in December 2015. The membership has worked diligently through KHI to improve patient safety and promote the development of optimal therapies for diseases that affect kidneys and the quality of life for millions of people.
View KHI's 2014-2015 Annual Report.
View the KHI Inaugural Review 2012-2014.
If you have any questions about KHI, or would like more information about becoming a member, please contact email@example.com.